Allergen-specific CD4+ T-cell receptor recognizing Tropomyosin-House Dust Mite peptide-MHC class II complex (TM-HDM-specific TCR)

The allergen-specific CD4+ T-cell receptor (TCR) recognizing Tropomyosin-House Dust Mite (TM-HDM) peptide-MHC class II complexes is a critical mediator of the allergic immune response to house dust mites (Source: PubMed PMID 28438887). These TCRs are expressed on the surface of CD4+ T helper cells and specifically bind to epitopes derived from tropomyosin (Der p 10), presented by Major Histocompatibility Complex (MHC) class II molecules on antigen-presenting cells (Source: WHO/IUIS Allergen Nomenclature). This interaction triggers T-cell activation and the subsequent secretion of Type 2 (Th2) cytokines such as IL-4, IL-5, and IL-13, which drive IgE production and eosinophilic inflammation (Source: PubMed PMID 25617777). In clinical practice, these TCR-MHC interactions are the primary targets for allergen-specific immunotherapy (AIT) and peptide-based vaccines, which aim to desensitize the immune system (Source: PubMed PMID 30243710). By modulating the signaling of these specific TCRs, therapies seek to induce immunological tolerance, characterized by T-cell exhaustion or the expansion of regulatory T cells. Understanding the specificity and repertoire of these TCRs is essential for developing precision medicine approaches for asthma and allergic rhinitis. Tropomyosin is a particularly important allergen due to its role as a pan-allergen, causing cross-reactivity between mites, crustaceans, and insects (Source: PubMed PMID 25617777). Advanced diagnostic tools like MHC-peptide tetramers allow for the direct visualization and quantification of these allergen-specific T cells in patient blood.

Other names

Der p 10-specific T-cell receptorTropomyosin-specific CD4+ TCRHouse dust mite-specific TCRHDM-specific TCRTropomyosin-specific T-cell receptor

Modulation of T-cell signaling to induce immunological tolerance, anergy, or regulatory T-cell differentiation.